neuradiab + radiotherapy + temozolomide

Neuradiab is a radioimmunoconjugate composed of the murine IgG2 anti-tenascin monoclonal antibody (mAb) 81C6 labeled with radioactive iodine-131. It specifically targets tenascin, an extracellular matrix protein highly overexpressed in gliomas and other cancers. By binding to tenascin on tumor cells and delivering localized beta radiation via iodine-131, Neuradiab aims to destroy residual cancer cells after surgical resection of brain tumors while sparing normal tissue. The drug has been primarily developed for glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. Clinical trials have evaluated its use in combination with standard therapies such as surgery, radiotherapy (XRT), and temozolomide chemotherapy. While early-phase studies showed promising survival benefits when added to standard care for GBM patients, a pivotal Phase III trial was terminated early due to logistical issues[1][3][4][5][7].

Other names

Iodine-131 monoclonal antibody 81C6Iodine131 monoclonal antibody 81C6Iodine 131 monoclonal antibody 81C6mAb 81C6mAb81C6mAb-81C6